• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    11-aza-10-deoxo-10-dihydroerythromycin A and derivatives thereof, and process for preparation thereof.
    公开号:SU1093253A3
    申请号:SU802903453
    申请日:1980-04-02
    公开日:1984-05-15
    发明作者:Кобрехель Габриела；Радоболиа Горьяна；Тамбурашев Зринка；Дьокич Слободан
    申请人:Плива Фармацевтическо-Химический Завод (Инопредприятие)；
    IPC主号:
    专利说明:

    boiling point of the reaction mixture to obtain compound 1e, which, in turn, can be reacted with acetic anhydride in pyridine at room temperature to obtain the desired product 1g, or reacted with p-toluenesulfonyl chloride in acetone in the presence of sodium carbonate at boiling point the reaction mixture to obtain the desired product 1h, or
    interaction with acetic or propionic anhydride in pyridine at room temperature for 30 min 10 days, obtaining, depending on the reaction time, O, N-diacyl (Gb) O, N-triaccine (1c) or O, N-tetraacyl (1g) derivatives which, in turn, can be treated with methanol in the presence of a 5% sodium bicarbonate solution to obtain the desired product 1e.
    The invention relates to a method for producing new compounds belonging to the class of erythromycins with anti-bacterial action, specifically to a method for producing derivatives of 11-aza-10-deoxo-10-dihydroerythromycin A of the general formula -r-nW B. E. v. RT RZ R, R Kg. H (la); R and Rj - acetyl, propionyl; R R ;, Rg. H (16) R, Rj, R3 -acetyl, propionyl; R4 Rg-H (1c), R, R2, Hz, R4-acetyl, propionyl; Rj. H (1g) RI - acetyl, propionyl; R, RJ R RS H (1d) R R, C 0; (1e) RRJ R3 -acetyl; R R C 0; (1g) R 4 - CHjCeH-SOj; R R3 - R RJ H; (Is). The purpose of the invention is to obtain new compounds that expand the arsenal of means of affecting a living organism with improved properties, compared with erythromycin A or Erythromycin A oxime, the closest structural analogs, achieved by synthesizing the latter based on the well-known reduction reaction: catalytic or borohydride flJ. The method for producing 11-aza-10-deoxo-10-dihydro-erythromycin A derivatives of general formula J is that the product of formula () with t.t. 128-131 C, - 54.630 (1% CH, Cfj), IR (SNA 1705 and 1730 cm-, C NMR () 163.9 ppm (C-10), obtained by rearranging according to the Weckmann erythromycin A oxime of the formula C 1 () 2 with 1-2 mol of p-toluenesulfonyl chloride and 2-4 mol of sodium bicarbonate at 5 C B a mixture of water and acetone, is subjected to catalytic hydrogenation in glacial acetic acid using noble metals or their oxides, such as Rh / C and PtOj, as catalysts at room temperature, pressure of 65-70 atm or reduced in absolute alcohol, such as methanol, with the help of complex metals, such as NaBH, at 4 s, to produce 11-aza-10-deoxy Yu-dihydroerythromycin A of formula | a, which, if necessary, is subjected to or react with ethylene carbonate in the presence of potassium carbonate in ethyl acetate at the boiling point of the reaction mixture to obtain Je, which, in turn, can be reacted with acetic anhydride to pyridine at room temperature. to obtain the desired product 1g, or to react with p-toluenesulfonyl chloride in acetone in the presence of sodium carbonate at the boiling point of the reaction mixture to obtain the desired product Is, or to react with acetic or propionic anhydride in pyridine at room temperature for 30 min. days, depending on the time of O, N-diacyl (16), O, N-triacylne {1c) or O, N-tetracyl (tr) derivatives, which, in turn, can be treated with methanol in the presence of 5% bicarbonate solution sodium to obtain the desired product 1D. Catalytic reduction is usually carried out at room temperature in a high pressure autoclave at a hydrogen pressure of 65-70 atm in glacial acetic acid with a substrate: catalyst ratio of 1: 24-1: 2. Noble metals or their oxides, for example, Rh / C or PtO, can be used as catalysts.
    Streptococcus faecal is
    ATCC 8043 Staphylococcus epidermidis
    ATCC 12228 Staphylococus aureus
    ATCC 6538-p Micrococcum flaous
    ATCC 10240 Sarcina lutea
    0.05 0.05 0.3 125 175 0.05 20
    0.1 0.1 0.5 200 200 2.5 100
    0.5 0.5 0.3 150 200 1.0 100
    0.3 0.1 0.05 50 175 0.5 20
    0.05 0.03 0.03 10 10 0.1 50 After completion of the hydrogenation (2-24 h), the reaction mixture is filtered, the filtrate is evaporated to a thick syrup under reduced pressure, the residue is dissolved in water and extracted several times with dichloromethane or chloroform pH 6.0j 6.5 and 8.3. The combined extracts at pH 8.3 are dried over KjCOj and evaporated to dryness. The reduction of complex metal hydrides, such as sodium borohydride, is carried out by gradually adding solid NaBH (more than about 4 hours) at 4 ° C to a methanol solution of the crude product, obtained by rearranging Ömman erythromycin A oxime, and then raw. 1 Naza-Yu-deoxo-U-dihydroerythromycin A is isolated in a known manner. The precipitate obtained is suspended in ether, stirred for about 2 hours while cooling with ice, filtered and the filtrate is evaporated. To confirm the antibacterial activity, some new compounds were tested in vitro on a series of gram-positive and gram-negative microorganisms. The results are shown in Table. 1 in vimi ny depressants; concentrations (MIC) in µg / ml as compared with erythromycin A and erythromycin A oxime. Table 1
    ATCC 9341 Bacillus cereus var.myc
    ATCC 11778 Bacillus subtilic
    ATCC 6633 Corynebacterium xerosis
    NCTC 9755 Brucella bronchlseptica
    ATCC 4617 Pseudomas aeruglnosa
    NCTC 10490 Kubsielea pneumoniae
    ATCC 10031 Schherichia cdli
    ATCC 10536
    Shigeela blexneri
    1Y819 / S Salmonella panama E erythromycin is considered new. When testing acute toxicity in albino mice using the Lithvilda-Wilcoxon method, 11-aza-10-deoxo 10-dihydro-erythromytia A was found to be less toxic than the original erythromycin A oxime (pl. 2). Table 2 Erythromycin A oxime.
    Continuation of table 1
    0.1 0.1 0.5 200 175 2.5 50
    0.05 0.1 5 175 200 0.5 100
    0.1 0.1 0.1
    10 1.0 1.0
    50 50 50
    5.0 5.0 5.0
    25 25 10
    25 50 10
    50 50 50 A; EO, erythromycin A oxime; - Arabic numerals connect | 1 of examples. The stability of the new compounds in the acidic medium was determined by acting on them for 30 minutes, 1 hour, 2 hours, 3 hours and 6 hours at pH 1.2, followed by determining the minimum inhibitory concentrations when testing the strain Staphylococcus aurens ATCC 6538-P, and It was found that the stability of the new compounds I and YI is in the stability range of the original antibiotic Erythromycin A oxime, but they are much more stable than erythromycin A (Table 3).
    ABOUT
    1/2
    one
    2
    3
    6 E Example 1. Beckman's rearrangement of erythromycin A oxime A. p-Toluenesulfonyl chloride (6.16 g, 0.032 mol in acetone (70 ml) and NaHCG, (5.4 g, 0.064 mol) in water (245 ml) are placed in an oxime solution erythromycin A (12 g, 0.016 mol) in acetone (200 ml) for 2 hours at 5 ° C. with stirring. The reaction mixture is stirred at this temperature for two hours, the acetone is evaporated. under reduced pressure, to the resulting suspension methylene chloride (50 ml), the reaction mixture at pH 7.9 is acidified with 1N HCl to pH 5.5, the layers are separated and the aqueous acid layer is extracted with chlorides methylene (2x50 ml). Extraction with dichloromethane is repeated at pH 6 (3x50 ml) and at pH 8 (5x100 ml) the combined dichloromethane extracts are dried over KjCOj and evaporated to dryness under vacuum. At pH 8 the product is isolated 8.4 g (71, 73%) with the following physical MP: 128-131 ° C; (cit) constants: -54.630 ° (1% CHjCl); IR (CHCIj) 1705 and 1730 cmH; NMR (SVS1z), 163.9 h. per million Cj-jHj gNjO j; М 730 Example 2. 11-aza-10-deokko (1). Sporo-10-dihydro-erythromycin A sob A. {The crude product of example 1 (6.0 g. 0.008 mol) is dissolved in an ice plate. Table 3
    1.0
    0.5 1.0 0.5 1.0 0.5 1.0 2.5 2.5 2.5 1.0 2.5 1.0 1.0 Erythromycin A; EO - erythromycin A oxime; Arabic numerals refer to new compounds from examples. hydrochloric acid (60 ml), PtO (0.25 g) is added and hydrogenation is carried out for 2 hours at room temperature and at 70 atm pressure with stirring. The catalyst is filtered off, the filtrate is evaporated to a thick syrup under reduced pressure, dissolved in water (160 ml) and then extracted at pH 6.0 and 6.5 (3x50 ml) and at pH 8.3 (3x100 ml) -. The combined extracts at pH 8.3 are dried over KjCGj and evaporated to dryness under vacuum. Chromatographically (dimethylformamide: methanol 3: 1) is obtained. Pure 11-az a-10-deoxo-10-dihydro-erythromycin A 4.8 g (79.56%): m.p. 113Pb C; (oi) ° - 33.9G (1% CH, C1j) j IR (CHCI,) 1725 cm- (C O lactone) and 1640 cm - (- W); NMR (CDCl1) 56.8 ppm (C-10); M 734. Example 3. 11-aza-10-deoxo-10-dihydro-erythromycin A (1). Method B. The crude product of Example 1 (2.0 g) was dissolved in glacial acetic acid (20 ml) and 5 wt.% Rh / C (1.0 g) was added and the hydrogenation was carried out for 8 hours at room temperature. temperature and pressure of 65 atm with stirring. The catalyst is filtered off and the product is taken up using the procedure described in Example 2. The desired product is obtained (64.65%) with physical constants similar to those of the compound of Example 2. Example 4. 11-aza-10-dex-10-dihydro erIthromycin A (H). Crto-comp. C. To a solution of the crude product of example 1 (12 g, 0.016 mol) in absolute methiol (300 ml) was added gradually over about 4 hours at 4 ° C with stirring g, 0.316 mol). After standing at room temperature for 24 hours, COj is introduced until the sedimentation of the precipitate is observed, the resulting filterless solution is obtained and the filtrate is evaporated to dryness under reduced pressure. The precipitate is dissolved in CHC1, (300 ml), the chloroform solution is washed with 10 weight. NaHCOj solution and water (2x150 ml), dried over KjCOj, filtered and evaporated to dryness under reduced pressure. The resulting precipitate was dissolved in CHCIj (100 ml), water (300 ml) was added to the solution, the reaction mixture having a pH of 11.3 was acidified to 2N. HC1 to fpR 2.5 and stirred for 15 min, 20 wt. % NaOH solution, the pH is adjusted to 6.0, the spoons are separated and the aqueous layer is extracted with chloroform (2x100 mp). The extraction with chloroform is repeated at pH 6.5 (3x50 ml) and at pH 8.3 (5x50), the extracts collected together are dried over Kj CO, and evaporated to dryness under reduced pressure. The precipitate, precipitated at pH 8.3, is suspended in dry ether, stirred for 2 hours while cooling with ice, filtered, and the filtrate is evaporated to give chromatography (dimethylformamide: methanol 3: 1) of pure 11-aza-10-deoxo-10-dihydro erythromycin A The resulting product 8.75 G (72.51%) is identical to the product of example 2. Example 5. 2, N-Diacetyl-11-aza-10-deoxo-10-dihydroerythromycin A (11). To a solution of 11-aza 10-deoxo-10-dihydro-erythromycin A (4.0 g, 0.0054 mol) in pyridine (80 ml) was added acetic anhydride (50 ml, 0.53 mol) and the mixture was left For 30 minutes at room temperature. The reaction is stopped by adding ice, the pH is adjusted to 9 with 20% w / w NaOH solution and extracted with chloroform (3x75 ml). Combined x.poroform extracts are rinsed with water (2x75 ml), dried over KjCO3, and evaporated to dryness under reduced pressure. The crude precipitate is precipitated from ether with petroleum ether. Yield 3.4 g (76.4%); m.p. 133-138 ° C; pK 6.7 (dimethylformamide) 66% by volume of water; IR (СНС1,) 1725 (С O lactone and ether), 1610 (-CO-Ng:) and 1235 cm (acetyl). Example 6. 2, N-dipropion-11-aza-10-deoxo-10-dihydro-erythromycin. A (11). From 11-aza-10-deoxo-10-dihydro-erythromycin A (2.0 g, 0.0027 mol) and propionic anhydride (25 ml, 0.194 mol), pure (chloroform: methanol 7: 3) 2, N-dipropionyl-11-aza-10-deoxo-10-dihydro-erythromycin A (1.35 g, 57.6%) by reaction in pyridine (40 ml) in accordance with the procedure described in example 5. So pl . 183-186 ° C; pKv 6.7 (dimethylformamide), 66 vol.% water; IR (CHCIj) 1725 (C O lactone and ether), 1615 (—CO — NO, and 1175 cm (propionyl). Example 7.2, 4 —H-triacet-11-aza-10-deoxo-10-dihydro-erythromycin A ( 1J1). To a solution of 11-aza-10-deoxo-10-dihydro-erythromycin A (1.0 g, 0.00136 mol) in pyridine (20 mp), acetic anhydride (20 ml, 0.212 mol) and a mixture of allowed to stand for 76 hours at room temperature. The reaction is stopped by adding ice, the pH of the reaction mixture is adjusted to 9 with 20% by weight NaOH solution and then extracted with chloroform (5x30 ml). The combined chloroform extracts are washed with saturated NaHCOj solution (3x30 ml) and water oh (2x30 mp), dried over KjCOj and evaporated to dryness under reduced pressure. The crude product is purified by precipitation from chloroform with petroleum ether. A pure (chloroform: methanol gformamide 100: 20: 2) triacetyl derivative (0.72 g, 61.5% ). Mp 148-156 C; (ot) -31.5 (dimethylformamide), 66 vol.% Water; IR (CHCIj) 1735 (C O lactone and ether), 1625 (-CO-NC) and 1235 cm (acetyl), M-860. Example 8. 24, 13, H-tetraacetyl (11-aza-10-deoxo-10-dihydroerythromycin A (1Y). A solution of 11-aza-10-deoxo-10-dihydro-erythromycin A (1.5 g, 002 mol) in pyridine (30 mp) and xusic anhydride (15 ml, 0.159 mol) are left to stand for 10 days - at room temperature and then processed as the triacetyl ether of example 7. After several subsequent precipitations from chloroform with petroleum ether, 2 ,, 13, N-tetraacetyl-11-aza-10-deoxo-10-dihydro-erythromycin A, 77% is obtained, 77%) . M.p. 110-115 ° C; (1, g, (ot) | -35.43 ° (1%, CHjClj); IR (CHCIj) 1735 (C O lactone and ether), 1624 (-CO-NC) and 1240 cm- (acetyl); Example 9. N-propionyl-11-aza-10-deoxo-10-dihydro-erythromycin A (Y), Compound C of Example 6 (2.15 g, 0.00254 mol) was dissolved in methanol (45 ml), added 5% by weight (weight of NaHCOj solution) (45 ml) and allowed to stand for 7 days at room temperature. Methanol is evaporated under reduced pressure, the pH of the aqueous suspension is adjusted to 9 using 1% 20% by weight NaOH solution and then extracted with chloroform (3x50 ml). The combined chloroform extracts are washed with water (2x50 ml), dried over Kj COj and evaporated dry under reduced pressure. Yield 1.84 (92.6%); mp 122-129 ° C; pKv 8.6 (dimethylformamide), 66% by water; IR (CHCIj) 1720 (C O lactone) 1610 ( —CO-N C). EXAMPLE 10 11-Aza-10-deoxo-10-dihydro-erythromycin A cyclic 13,14-carbonate 4Y1). 11-Aza-10-deoxo-10-dihydroerythrocycin A (1.0 g, 0.00136 mol) was dissolved in ethyl acetate (10 ml), KjCOj (0.2 g, 0.0014 mol ) and ethylene carbonate (0.5 g 0.00568 mol) and then it is copied for 2 hours under reflux. Reaction: the mixture is cooled, filtered and evaporated to a thick oil under vacuum, from which 11-aza-10-deoxo-10-dihydro-erythromycin A cyclic 13,14-carbonate is precipitated by adding water (approximately 25 ml) 0.85 g, 82.1%). T.ll. 129 135 С; IR (CHC1) 1790 (C O carbonate), 1725 (C O lactone); M 760. Example 11. 2,4, K-triacetyl-11-aza-10-deoxy-10-dihydro-eryt romicin A cyclic 13,14-carbonate (YIt). 10 3 Cyclic 13,14-carbonate 11-aza-10-deoxo-10-dihydro-erythromycinI A (0.5 g, 0.00065 mol) is dissolved in pyridine (2.5 ml), acetic anhydride is added to the solution (2.5 ml, 0.00265 mol) and left to stand for 28 hours at room temperature. The reaction is stopped by adding ice and the product is extracted with chloroform (3 x 15 ml). The combined chloroform extracts are washed with water (2x10 ml), dried over, and evaporated to dryness in vacuo. Yield 0.58 g (98.5%); M.p. 109-117 ° C; IR (CHCl 3) 1800 (C O carbonate), 1730 (C O lactone and ester) and 1625 (-CON) and 1240 cm-1 (acetate); H NMR (CDCIj) 2.06 (3N), 2.1 (3N), 2.12 (3N), 2.3 (6H), and 3.3 (3N) ppm. Example 12. YY (4-methyl-benzenesulfonyl) -11 aza-10-deox-o-10-dihydro-erythromycin A (Y111). To a solution of 11-aza-10-deoxo-10-dihydro-erythromycin A (4.0 g, 0.0054 mol) in dry acetone (120 ml) was added Na CO 2 H 3 O (13.8 g, O, 11 mol ) and then a solution of rt-toluenesulfonyl chloride (0.24 g, 0.0327 mol) in dry acetone (120 ml) is added with vigorous stirring and refluxed for 12 hours. The reaction mixture is filtered and the filtrate is evaporated to dryness vacuum. The precipitate was dissolved in 100 ml of methylene chloride, water (40 ml) was added to the solution, the pH of the resulting solution was 7, the pH was adjusted to 6 with 1N HCl, the layers were separated and the aqueous layer was extracted with methylene chloride (3x4 ml). After drying the combined extracts and evaporation of the solvent, the desired product is obtained 3.6 g (74.39%), which is purified by chromatography on silica gel. M.p. 150-153 0; (ot) -9.04 ° (1% CHjCl); IR (CHCIj) 1730 (C O. lactone), 1600.755 and 655 (p-phenyl) and 1340 cM-4-SO, j-). Example 13. 11-Aza-10-deoxo-10-dihydroepitromycin A (1). Method D. To a solution of the crude product (6.0 g, 0.008 mol) from Example 1 in glacial acetic acid (60 ml) was added PtOj (0.75 g) and subjected to hydrogenation for 4 hours with stirring at room temperature and pressure
    13109325314
    5 atm. The catalyst is filtered off having the same physicochemical product isolated as in example 2. properties as well as the products obtained The product is obtained (4.6 g, 76.2%), in example 2. M 888.
    权利要求:
    Claims (2)
    [1]
    (57.) 1. METHOD FOR PRODUCING 11-AZA-10-DIOXO-10-DIGYDROERITHROMYCIN A DERIVATIVES of the General Formula I h o ^ s! Nz
    SNZ
    0CH 5 where R, = R 2 = R 3 = R 4 = Rg- = H (/ a); Rf and R 2 are acetyl, propionyl; R 3 ". = R 4 = R s = H (J6); R 4> R 2 , R 3 - acetyl, propionyl; R 4 = R g = H (1c) R 4 , R 2 , R 3 , R + - acetyl, propionyl; Rg = H ([g) Rj, - acetyl, propionyl; R 2 = R 3 = R 4 = R 5 = H (1e) R 4 = R 2 = = R 3 = H, R 4 = R 5 => C = 0; (Je) R, = R, = R 3 is acetyl; R. = R s = = C = O; (Tg) R 3 = 4 - CH 3 C 6 H 4 -S0 2 ;
    R 2 = R 3 = R 4 = R s = H; (fa) characterized in that the product of the formula C, 3 H € fc N 2 O 12 (M + 73O) with so pl. 128-131 ° C, - - 54.630 (1%
    СН 2 С ^>, IR (СНС ^) 1705 and 1730 cm ' 1 , 13 С NMR (CDC <j) 163.9 ppm (С - 10) obtained by Beckman rearrangement of erythromycin A oxime of formula fl
    SU <„> 1093253 with 1-2 mol of η-toluene sulfochloride and
    [2]
    2-4 mol of sodium bicarbonate at 5 0 С in a mixture of water and acetone, is subjected to [Catalytic hydrogenation in glacial acetic acid using • noble metals or their oxides, such as Rh / 'C or PtO 2 , as catalysts at room temperature , pressure 65-70.atm or reduced in absolute alcohol, such as methanol, with the help of complex metal hydrides, such as NaBH. 4 , at 4 ° C, to give 11-aza-10-deoxy-10-dihydroerythromycin A of formula fa, which, if necessary, is subjected to or reacted with ethylene carbonate in the presence of>
    potassium carbonate in ethyl acetate at the boiling point of the reaction mixture to give compound 1e, which, in turn, can be reacted with acetic anhydride in pyridine at room temperature to give the desired product] g, or reacted with p-toluenesulfonyl chloride in acetone in the presence of carbonate sodium at the boiling point of the reaction mixture to obtain the desired product Xs, or by reaction with acetic or propionic anhydride in pyridine at room temperature for 30 minutes 10 days, gender learning, depending on the reaction time, O, N-diacyl (GB), 0, N-triacyl (1c) or O, N-tetraacyl (1g) derivatives, which, in turn, can be treated with methanol in the presence of 5% - sodium bicarbonate solution to obtain the target product 1d.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1093253A3|1984-05-15|Process for preparing derivatives of 11-aza-10-deoxo-10-dihydroerythromycin a
    DK172636B1|1999-03-22|6-o-methylerythromycin a derivative
    CA1239639A|1988-07-26|Epimeric azahomoerythromycin a derivative andintermediates therefor
    RU2230748C2|2004-06-20|Method for preparing clarithromycin as crystals of form ii
    CA2184734C|1999-08-03|3&#39;&#39;-desmethoxy derivatives of erythromycin and azithromycin
    US5869629A|1999-02-09|Synthesis of 9-deoxo-9a-aza-11,12-deoxy-9a-methyl-9a-homoerythromycin A 11,12 Hydrogenorthoborate dihydrate and a process for the preparation of azitromicin dihydrate
    Tsuji et al.1978|Trichostatin C, a glucopyranosyl hydroxamate
    EP0080818A1|1983-06-08|Erythromycin B derivatives
    DK157495B|1990-01-15|ANALOGY PROCEDURE FOR PREPARING 4AE-EPI-ERYTHROMYCINE A OR DERIVATIVES THEREOF
    US4492688A|1985-01-08|Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin A and intermediates therefor
    EP0132944A1|1985-02-13|Antibacterial homoerythromycin A derivatives and intermediates therefor
    KR100556335B1|2006-03-03|6r-3,6-dideoxy-l-arabino-hexopyranosyl heptanoic acid, preparation process for the same and dauer effect thereof
    HU211975A9|1996-01-29|Derivatives of tylosin and 10,11,12,13-tetrahydrotylosin and their use in pharmaceuticals
    KR920000646B1|1992-01-20|Fluoro-substituted epipodophyllo-toxin glucosides
    EP0063489A1|1982-10-27|4&#34;-Modified methylene oleandomycins
    Kurihara et al.1996|Cladinose analogues of sixteen-membered macrolide antibiotics I. Synthesis of 4-O-alkyl-l-cladinose analogues via glycosylation
    SU650507A3|1979-02-28|Method of obtaining glycoside antibiotics or their hydrochlorides
    CA1194864A|1985-10-08|19-deformyl-deoxy-desmycosin
    US5210227A|1993-05-11|Immunosuppressive compounds
    DE69935250T2|2007-10-31|OLEANDOMYCIN DERIVATIVES
    CA1115697A|1982-01-05|4&#34;-deoxy-4&#34;-arylglyoxamido- andaroylthioformamido derivatives ofoleandomycin and its esters
    JP2843695B2|1999-01-06|10,11,12,13-Tetrahydro-desmycosin derivative, process for producing the same and use thereof as a medicament
    CA1213278A|1986-10-28|3-azinomethyl rifamycins
    Gernigon et al.2012|Synthesis and antibacterial activity of novel neamine derivatives: preponderant role of the substituent position on the neamine core
    KR790001501B1|1979-10-24|Process for preparing midecamycine derivatives
    同族专利:
    公开号 | 公开日
    GB2047247A|1980-11-26|
    DE3051049C2|1991-08-22|
    JPS57114598A|1982-07-16|
    DE3012533C2|1988-09-29|
    GB2047247B|1983-05-25|
    YU76879A|1982-10-31|
    CH646440A5|1984-11-30|
    SI7910768A8|1996-06-30|
    US4328334A|1982-05-04|
    YU43116B|1989-04-30|
    AT369750B|1983-01-25|
    JPS6364438B2|1988-12-12|
    CA1142517A|1983-03-08|
    ATA179380A|1982-06-15|
    DE3012533A1|1980-10-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    YU31319B|1967-08-03|1973-04-30|Pliva Pharm & Chem Works|Postupak za dobijanje acil derivata eritromicin oksima|
    GB1100504A|1967-08-16|1968-01-24|Pliva Pharm & Chem Works|Erythromycin oxime and 9-amino-3-o-cladinosyl-5-o-desosaminyl-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethylpentadecane-13-olide|
    US3652537A|1969-11-21|1972-03-28|Lilly Co Eli|Epierythromycylamine and epierythromycyl b amine|JPS5788193A|1980-11-21|1982-06-01|Pliva Pharm & Chem Works|11-aza-10-deoxo-10-dihydroerythromycin a, derivatives and manufacture|
    YU43006B|1981-03-06|1989-02-28|Pliva Pharm & Chem Works|Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof|
    ZA835204B|1982-07-19|1985-02-27|Pfizer|N-methyl 11-aza-10-deoxo-10-dihydroerythromycin a,intermediates therefor and processes for their preparation|
    US4474768A|1982-07-19|1984-10-02|Pfizer Inc.|N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor|
    PH19293A|1982-11-15|1986-03-04|Pfizer|Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof|
    US4526889A|1982-11-15|1985-07-02|Pfizer Inc.|Epimeric azahomoerythromycin A derivative, intermediates and method of use|
    EP0132026B1|1983-05-23|1986-12-30|Pfizer Inc.|Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin a and intermediates therefor|
    JPH0149356B2|1983-05-23|1989-10-24|Pfizer|
    US4464527A|1983-06-30|1984-08-07|Pfizer Inc.|Antibacterial 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin A derivatives and intermediates therefore|
    YU43658B|1983-07-18|1989-10-31|Pliva Pharm & Chem Works|Process for preparing 7,16-dioxa-2-aza-10-0-cladinosyl-12,0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclohexadeca-1-ene-8|
    GR80277B|1983-09-06|1985-01-04|Pfizer|Azahomoerythromycin b derivatives and intermediates therefor|
    US4465674A|1983-09-06|1984-08-14|Pfizer Inc.|Azahomoerythromycin D derivative and intermediates therefor|
    US4492688A|1983-11-25|1985-01-08|Pfizer Inc.|Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin A and intermediates therefor|
    US4518590A|1984-04-13|1985-05-21|Pfizer Inc.|9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method|
    US4512982A|1984-04-13|1985-04-23|Pfizer Inc.|9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method|
    SI8611592A8|1986-09-12|1995-04-30|Pliva Pharm & Chem Works|Process for preparing complexes of N-methyl-11-aza-10-deoxo-10-dihydroeritromicine A and 11-aza-10-deoxo-10-dihydroeritromicine A with metals|
    DE3860503D1|1987-09-03|1990-10-04|Pliva Pharm & Chem Works|10-DIHYDRO-10-DEOXO-11-AZAERYTHRONOLID-A COMPOUNDS, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS AND THE PRODUCTION THEREOF.|
    US5075289A|1988-06-07|1991-12-24|Abbott Laboratories|9-r-azacyclic erythromycin antibiotics|
    US5912331A|1991-03-15|1999-06-15|Merck & Co., Inc.|Process for the preparation of 9-deoxo-9-hydroxyiminoerythromycin A|
    US5554605A|1991-04-09|1996-09-10|Abbott Laboratories|Macrocyclic lactam prokinetic agents|
    US5215980A|1992-01-17|1993-06-01|Merck & Co., Inc.|10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof|
    US5985844A|1992-03-26|1999-11-16|Merck & Co., Inc.|Homoerythromycin A derivatives modified at the 4"-and 8A-positions|
    US5189159A|1992-04-02|1993-02-23|Merck & Co., Inc.|8a-AZA-8a-homoerythromycin cyclic iminoethers|
    US5210235A|1992-08-26|1993-05-11|Merck & Co., Inc.|Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics|
    HRP930014B1|1993-01-08|1998-12-31|Đokić Slobodan|
    US5332807A|1993-04-14|1994-07-26|Merck & Co., Inc.|Process of producing 8A- and 9A-azalide antibiotics|
    WO1994026758A1|1993-05-19|1994-11-24|Pfizer Inc.|Intermediate for azithromycin|
    ES2122905B1|1996-07-11|1999-11-16|Astur Pharma Sa|SYNTHESIS OF 11,12-HYDROGENOORTOBORATE 9-DESOXO-9A-AZA-11,12-DESOXI-9A-METHYL-9A-HOMOERYTHROMYCIN A. A PROCEDURE FOR THE PREPARATION OF 9-DESOXO-9A-AZA-9A-METHYL-9A -HOMOERYTHROMYCIN TO DIHYDRATE .|
    DE69837007T2|1997-09-10|2007-11-22|Merial Ltd.|USE OF 9A-AZALIDES AS ANTIMICROBIAL AGENTS FOR ANIMALS|
    US6339063B1|1997-09-10|2002-01-15|Merck & Co., Inc.|9a-azalides as veterinary antimicrobial agents|
    HRP970714B1|1997-12-31|2003-08-31|Pliva Pharm & Chem Works|Beta,beta-disubstituted derivatives of 9-deoxo-9a-n-ethenyl-9a-aza-9a-homoerythromycin a|
    AP9801420A0|1998-01-02|1998-12-31|Pfizer Prod Inc|Novel macrolides.|
    HRP980189B1|1998-04-06|2004-04-30|Pliva Pharm & Chem Works|Novel 15-membered lactams ketolides|
    WO2000031097A1|1998-11-20|2000-06-02|Pfizer Products Inc.|13-membered azalides and their use as antibiotic agents|
    HRP990116B1|1999-04-20|2007-10-31|GLAXOSMITHKLINE istraživački centar Zagreb d.o.o.|NOVEL 8a AND 9a- 15-MEMBERED LACTAMES|
    HRP990130B1|1999-05-03|2004-06-30|Pliva D D|HALOGEN DERIVATIVES 9a-N-- AND 9a-N--9-DEOXO-9a-AZA-9a OF HOMOERYTHROMYCIN A|
    WO2000071557A1|1999-05-24|2000-11-30|Pfizer Products Inc.|13-methyl-erythromycin derivatives|
    US6764996B1|1999-08-24|2004-07-20|Abbott Laboratories|9a-azalides with antibacterial activity|
    EP1101769A3|1999-11-18|2001-10-24|Pfizer Products Inc.|Nitrogen containing erythromycin derivatives|
    EP1304326B1|2000-07-25|2006-03-15|Laboratorio Silanes, S.A. de C.V.|Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle hexadeca-1-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a|
    JP2004506664A|2000-08-23|2004-03-04|ウォックハート・リミテッド|Method for producing anhydrous azithromycin|
    ES2179756B1|2000-11-30|2004-10-01|Ercros Industrial, S.A.|PROCEDURE FOR OBTAINING AZAERITHROMYCIN.|
    KR100491183B1|2001-03-21|2005-05-25|한미약품 주식회사|Process of preparing azithromycin and crystalline 9-deoxo-9a-aza-9a-homoerythromycin a hydrate used therein|
    RU2263117C2|2001-04-27|2005-10-27|Пфайзер Продактс Инк.|Method for preparing 4''-substituted derivatives of 9-deoxo-9a-aza-9a-homoerythromycin a|
    HRP20010301A2|2001-04-27|2001-12-31|Pliva D D|New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases|
    US6861413B2|2001-05-22|2005-03-01|Pfizer Inc.|Stable non-dihydrate azithromycin oral suspensions|
    KR100574153B1|2001-05-22|2006-04-25|화이자 프로덕츠 인코포레이티드|Crystal forms of azithromycin|
    AP1729A|2001-08-21|2007-03-26|Pfizer Prod Inc|Single dose azithromycin for treating respiratory infections.|
    WO2003070174A2|2002-02-15|2003-08-28|Sympore Gmbh|Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof|
    US20060069047A1|2002-02-15|2006-03-30|Michael Burnet|Antibiotic conjugates|
    US20040186063A1|2002-02-15|2004-09-23|Hans-Jurgen Gutke|Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof|
    US20060099660A1|2002-02-15|2006-05-11|Synovo Gmbh|Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof|
    ITMI20021209A1|2002-06-04|2003-12-04|Chemi Spa|HIGH-PURITY AZITROMYCIN PREPARATION PROCESS|
    HRP20020779A2|2002-09-27|2005-02-28|PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o.|NEW 3-DECLADINOSYL DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICIN A 9a, 11-CYCLIC CARBAMATES|
    ITMI20022292A1|2002-10-29|2004-04-30|Zambon Spa|9A-AZALIDS WITH ANTI-INFLAMMATORY ACTIVITY.|
    HRP20020885B1|2002-11-11|2007-05-31|GLAXOSMITHKLINE istraživački centar Zagreb d.o.o.|SUBSTITUTED 9a-N-{N'-[4-PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A|
    HRP20020991A2|2002-12-12|2005-02-28|PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o.|N"-Substituted 9a-N-, 9a-N-, 9a-N--N'-carbamoyl-Gamma? -aminopropyl) and 9a-N--N'-thiocarbamoyl-Gamma? -aminopropyl) derivatives of 9-de|
    HRP20030381B1|2003-05-14|2007-05-31|GLAXOSMITHKLINE istraživački centar Zagreb d.o.o.|3-DECLADINOZYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICYNE A|
    EP1661904A1|2003-08-22|2006-05-31|Meiji Seika Kaisha Ltd.|Novel azalide and azalactam derivatives and process for the production of the same|
    US7468428B2|2004-03-17|2008-12-23|App Pharmaceuticals, Llc|Lyophilized azithromycin formulation|
    US20060116336A1|2004-03-17|2006-06-01|American Pharmaceutical Partners, Inc.|Lyophilized azithromycin formulation|
    AU2006274197A1|2005-07-26|2007-02-01|Merckle Gmbh|Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase|
    CN102260306B|2011-07-22|2012-07-18|山东鲁抗舍里乐药业有限公司|Novel method for preparing tulathromycin|
    CN102863486A|2012-09-18|2013-01-09|太仓市运通化工厂|Synthesis method of 9-desoxy-9a-aza-9a-erythromycin thiocyanate|
    US11059846B2|2017-02-22|2021-07-13|ISR Immune System Regulation Holding AB |Immune stimulating compound|
    WO2018153954A1|2017-02-22|2018-08-30|Immune System Regulation Holding Ab|Novel immune stimulating macrolide|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    YU768/79A|YU43116B|1979-04-02|1979-04-02|Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox|
    [返回顶部]